Web app to help breast cancer patients stick to their hormone therapy
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
This study is testing a web app that helps women with early-stage breast cancer remember to take their hormone therapy and manage side effects better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 4 sites (Atlanta, Georgia and 3 other locations) |
| Trial ID | NCT05488145 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the feasibility of a web-based application designed to improve adherence to endocrine therapy among patients with early-stage hormone receptor-positive HER2-negative breast cancer. The app provides weekly reminders, educational content on side effect management, and direct communication with healthcare providers. By enhancing patient education and support, the study aims to determine if the app can help maintain high adherence levels to treatment. A total of 30 patients will participate in this single-arm feasibility study over a duration of three months.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with early-stage hormone receptor-positive, HER2-negative breast cancer who have recently started endocrine therapy.
Not a fit: Patients who are HER2-positive will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve treatment adherence and outcomes for breast cancer patients.
How similar studies have performed: Other studies have shown promise in using digital interventions to improve medication adherence, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Early-stage hormone receptor positive, HER2-negative breast cancer who have completed all recommended (neo)adjuvant chemotherapy, surgery and/or radiation therapy * Age \>= 18 * Started on an aromatase inhibitor or Tamoxifen within less than or equal to six months prior to time of enrollment * Access to internet from a desktop or a smartphone * Ability to speak English Exclusion Criteria: * Patients who are her2 neu positive
Where this trial is running
Atlanta, Georgia and 3 other locations
- Emory University Hospital Midtown — Atlanta, Georgia, United States (Recruiting)
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States (Recruiting)
- Emory Saint Joseph's Hospital — Atlanta, Georgia, United States (Recruiting)
- Emory Johns Creek Hospital — Johns Creek, Georgia, United States (Not_yet_recruiting)
Study contacts
- Principal investigator: Jane L. Meisel, MD — Emory University Hospital/Winship Cancer Institute
- Study coordinator: Jane L. Meisel, MD
- Email: jane.l.meisel@emory.edu
- Phone: 404-778-1900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.